Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami

Patients with heavily pretreated myeloma tended to have “really amazing results” with the CAR-T cell therapy, Carvykti.

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

The Food and Drug Administration approved the CAR-T cell therapy, Carvykti, for previously treated patients with multiple myeloma.

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

There is no difference in treatment for non-secretory multiple myeloma and multiple myeloma, an expert told CURE®.

Of everything I've ever done, I wonder how my multiple myeloma came to be.